Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.15 (market cap $119.10M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.92 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 212.2× Roundhill NVDA WeeklyPay ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 50 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NVDW | RPRX | |
|---|---|---|
Market Cap | $119.10M | $25.27B |
Volume | 44,838 | 3,671,183 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $63.96 |
52-Week Low | $31.88 | $35.44 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
